Intellia Therapeutics Appoints Derek Hicks as Chief Business Officer
20 Décembre 2021 - 1:30PM
Intellia Therapeutics, Inc. (NASDAQ: NTLA), a leading genome
editing company focused on developing curative therapeutics using
CRISPR/Cas9 technology both in vivo and ex vivo, today announced
the appointment of Derek Hicks to a newly created position as
Executive Vice President, Chief Business Officer.
Mr. Hicks joins Intellia with more than 25 years of combined
business, leadership and biotechnology experience, having most
recently served as Head of Business Development at Spark
Therapeutics. While at Spark, he was responsible for business
development strategy, search and evaluation, licensing and key
partnership activities. Prior to this role, Mr. Hicks spent 18
years at Pfizer in a variety of business and corporate development
roles culminating with his position as Vice President, Corporate
Development, World-Wide Business Development.
“As Intellia continues to expand its leadership position in the
field of genome editing, our ability to grow our pipeline, imagine
new therapeutic possibilities and collaborate with leading
organizations will be key to our future success. I am thrilled to
welcome Derek to Intellia’s executive team as we enter the next
chapter in our evolution,” said Intellia President and Chief
Executive Officer John Leonard, M.D. “Derek is an accomplished
business leader who shares Intellia’s values and commitment to
bringing forth life-changing therapies for patients. He has a long,
successful history of leading corporate and business development
efforts in the biotechnology and pharmaceutical industry. I am
confident his expertise will complement Intellia’s strong legacy of
identifying and executing upon value-adding partnerships and
corporate development opportunities critical to our mission of
building the industry’s most innovative genome editing
company.”
“I could not be more excited to join Intellia at this
transformational time as the team is just beginning to realize the
full potential of genome editing,” said Mr. Hicks. “Intellia has
clearly been a pioneer in the space, and I look forward to working
with the Intellia team and our partners in maximizing the impact of
its world-class science for the benefit of patients.”
Mr. Hicks earned both a Bachelor’s and Master’s of Science
degree in mechanical engineering from the University of Connecticut
and an MBA in finance from Indiana University Kelly School of
Business.
About Intellia Therapeutics
Intellia Therapeutics, a leading clinical-stage genome editing
company, is developing novel, potentially curative therapeutics
using CRISPR/Cas9 technology. To fully realize the transformative
potential of CRISPR/Cas9, Intellia is pursuing two primary
approaches. The company’s in vivo programs use intravenously
administered CRISPR as the therapy, in which proprietary delivery
technology enables highly precise editing of disease-causing genes
directly within specific target tissues. Intellia’s ex vivo
programs use CRISPR to create the therapy by using engineered human
cells to treat cancer and autoimmune diseases. Intellia’s deep
scientific, technical and clinical development experience, along
with its robust intellectual property portfolio, have enabled the
company to take a leadership role in harnessing the full potential
of CRISPR/Cas9 to create new classes of genetic medicine. Learn
more at intelliatx.com. Follow us on
Twitter @intelliatweets.
Forward-Looking Statements
This press release contains “forward-looking statements” of
Intellia Therapeutics, Inc. (“Intellia”) within the meaning of the
Private Securities Litigation Reform Act of 1995. These
forward-looking statements include, but are not limited to, express
or implied statements regarding Intellia’s ability to advance and
expand the CRISPR/Cas9 technology to develop into human therapeutic
products, as well as our CRISPR/Cas9 intellectual property
portfolio; achieve stable or effective genome editing; the timing
and potential achievement of milestones to advance our pipeline and
grow as a company; and the anticipated contribution of the members
of our board of directors and our executives to our operations and
progress.
Any forward-looking statements in this press release are based
on management’s current expectations and beliefs of future events
and are subject to a number of risks and uncertainties that could
cause actual results to differ materially and adversely from those
set forth in or implied by such forward-looking statements. These
risks and uncertainties include, but are not limited to: risks
related to Intellia’s ability to protect and maintain its
intellectual property position; risks related to Intellia’s
relationship with third parties, including its licensors and
licensees; risks related to the ability of its licensors to protect
and maintain their intellectual property position; uncertainties
related to the authorization, initiation and conduct of studies and
other development requirements for its product candidates; the risk
that any one or more of Intellia’s product candidates will not be
successfully developed and commercialized; the risk that the
results of preclinical studies or clinical studies will not be
predictive of future results in connection with future studies; and
the risk that Intellia’s collaborations with Regeneron or its other
collaborations will not continue or will not be successful. For a
discussion of these and other risks and uncertainties, and other
important factors, any of which could cause Intellia’s actual
results to differ from those contained in the forward-looking
statements, see the section entitled “Risk Factors” in Intellia’s
most recent annual report on Form 10-K as well as discussions of
potential risks, uncertainties, and other important factors in
Intellia’s other filings with the Securities and Exchange
Commission (“SEC”). All information in this press release is as of
the date of the release, and Intellia undertakes no duty to update
this information unless required by law.
Intellia Contacts:
Investors:Ian KarpSenior Vice President,
Investor Relations and Corporate
Communications+1-857-449-4175ian.karp@intelliatx.com
Lina LiDirector, Investor
Relations+1-857-706-1612lina.li@intelliatx.com
Media:Matt CrensonTen Bridge
Communications+1-917-640-7930media@intelliatx.commcrenson@tenbridgecommunications.com
Intellia Therapeutics (NASDAQ:NTLA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Intellia Therapeutics (NASDAQ:NTLA)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024